Felix A Ratjen

List of Publications by Year in Descending Order

319 papers	15,500 citations	58 h-index	116 g-index
357 ext. papers	18,927 ext. citations	7.1 avg, IF	6.52 L-index

#	Paper	IF	Citations
319	Lower airway nitrogen oxide levels in children with primary ciliary dyskinesia is linked to neutrophilic inflammation.. *Journal of Pediatrics*, **2022**,	3.6	
318	Re: Impact of spiroware re-analysis method on multiple-breath washout outcomes in children with cystic fibrosis; M.A. Oestreich, F. Wyler, P. Latzin et al.. *Journal of Cystic Fibrosis*, **2022**,	4.1	0
317	Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.. *Npj Genomic Medicine*, **2022**, 7, 28	6.2	0
316	Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis. *European Respiratory Journal*, **2021**, 58,	13.6	3
315	Newborn screening for cystic fibrosis: Role of primary care providers in caring for infants with positive screening results. *Canadian Family Physician*, **2021**, 67, e144-e152	0.9	1
314	Primary care providers' role in newborn screening result notification for cystic fibrosis. *Canadian Family Physician*, **2021**, 67, 439-448	0.9	
313	Clinical Effectiveness of Elexacaftor/Tezacftor/Ivacaftor in People with Cystic Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	10
312	A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients. *Stem Cell Reports*, **2021**, 16, 2825-2837	8	5
311	Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis. *EBioMedicine*, **2021**, 73, 103660	8.8	2
310	Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in paediatric cystic fibrosis. *European Respiratory Journal*, **2021**, 57,	13.6	1
309	Infant spirometry as a predictor of lung function at early childhood in cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2021**, 20, 937-940	4.1	1
308	Comparison of Functional Free-Breathing Pulmonary H and Hyperpolarized Xe Magnetic Resonance Imaging in Pediatric Cystic Fibrosis. *Academic Radiology*, **2021**, 28, e209-e218	4.3	9
307	PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. *Journal of Cystic Fibrosis*, **2021**, 20, 205-212	4.1	11
306	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. *Thorax*, **2021**, 76, 1255-1265	7.3	1
305	Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations. *Pediatric Pulmonology*, **2021**, 56, 2036-2042	3.5	
304	A multimodal approach to detect and monitor early lung disease in cystic fibrosis. *Expert Review of Respiratory Medicine*, **2021**, 15, 761-772	3.8	3
303	The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. *Journal of Personalized Medicine*, **2021**, 11,	3.6	1

302	Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study. *Journal of Cystic Fibrosis*, **2021**,	4.1	2
301	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. *Annals of Internal Medicine*, **2021**, 174, 1035-1036	8	2
300	The remaining barriers to normalcy in CF: Advances in assessment of CF lung disease. *Pediatric Pulmonology*, **2021**, 56 Suppl 1, S90-S96	3.5	0
299	Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial. *Annals of the American Thoracic Society*, **2021**, 18, 75-83	4.7	15
298	Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 977-986	10.2	9
297	Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 243-249	4.1	11
296	Aerosolized lancovutide in adolescents (≥12 years) and adults with cystic fibrosis - a randomized trial. *Journal of Cystic Fibrosis*, **2021**, 20, 61-67	4.1	2
295	Unsupervised phenotypic clustering for determining clinical status in children with cystic fibrosis. *European Respiratory Journal*, **2021**, 58,	13.6	1
294	CFTR-function and ventilation inhomogeneity in individuals with cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 641-647	4.1	1
293	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 1018-1025	4.1	0
292	Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. *Annals of the American Thoracic Society*, **2021**, 18, 1397-1405	4.7	9
291	Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials. *Journal of Cystic Fibrosis*, **2021**,	4.1	1
290	Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. *Lancet Respiratory Medicine,the*, **2021**, 9, 977-988	35.1	7
289	Utility of modified Rankin Scale for brain vascular malformations in hereditary hemorrhagic telangiectasia. *Orphanet Journal of Rare Diseases*, **2021**, 16, 390	4.2	
288	Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. *Lancet Respiratory Medicine,the*, **2021**, 9, 721-732	35.1	8
287	Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth. *Genetics in Medicine*, **2021**, 23, 927-933	8.1	3
286	Neurovascular Manifestations in Pediatric Patients With Hereditary Haemorrhagic Telangiectasia.. *Pediatric Neurology*, **2021**, 129, 24-30	2.9	0
285	Primary care providers' role in newborn screening result notification for cystic fibrosis. *Canadian Family Physician*, **2021**, 67, 439-448	0.9	

284	Newborn screening for cystic fibrosis. *Canadian Family Physician*, **2021**, 67, e144-e152	0.9	2
283	Normative data for multiple breath washout outcomes in school-aged Caucasian children. *European Respiratory Journal*, **2020**, 55,	13.6	40
282	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. *The Cochrane Library*, **2020**, 5, CD006961	5.2	
281	Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study. *Journal of Cystic Fibrosis*, **2020**, 19, 931-933	4.1	16
280	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *The Cochrane Library*, **2020**, 6, CD010004	5.2	1
279	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. *The Cochrane Library*, **2020**, 6, CD009528	5.2	2
278	Evaluation of a multiple breath nitrogen washout system in children. *Pediatric Pulmonology*, **2020**, 55, 2108-2114	3.5	2
277	Building global development strategies for cf therapeutics during a transitional cftr modulator era. *Journal of Cystic Fibrosis*, **2020**, 19, 677-687	4.1	8
276	Persistent ventilation inhomogeneity after an acute exacerbation in preschool children with recurrent wheezing. *Pediatric Allergy and Immunology*, **2020**, 31, 608-615	4.2	3
275	Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 492-498	4.1	2
274	The utility of moment ratios and abbreviated endpoints of the multiple breath washout test in preschool children with cystic fibrosis. *Pediatric Pulmonology*, **2020**, 55, 649-653	3.5	5
273	Cystic Fibrosis: Treatment **2020**, 453-466		
272	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. *Journal of Cystic Fibrosis*, **2020**, 19, 370-375	4.1	10
271	Long-term effect of CFTR modulator therapy on airway nitric oxide. *European Respiratory Journal*, **2020**, 55,	13.6	3
270	Assessing the feasibility of hyperpolarized Xe multiple-breath washout MRI in pediatric cystic fibrosis. *Magnetic Resonance in Medicine*, **2020**, 84, 304-311	4.4	8
269	Integrating the multiple breath washout test into international multicentre trials. *Journal of Cystic Fibrosis*, **2020**, 19, 602-607	4.1	17
268	Paediatric reproducibility limits for the forced expiratory volume in 1 s. *Thorax*, **2020**, 75, 891-896	7.3	4
267	Clinical Outcomes Associated with Complex Infection in Patients with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2020**, 17, 1542-1548	4.7	6

266	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. *Annals of Internal Medicine*, **2020**, 173, 989-1001	8	79
265	Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis. *Frontiers in Pharmacology*, **2020**, 11, 576293	5.6	0
264	Genotype-Phenotype Correlations in Children with HHT. *Journal of Clinical Medicine*, **2020**, 9,	5.1	7
263	Multiple breath washout in bronchiectasis clinical trials: is it feasible?. *ERJ Open Research*, **2020**, 6,	3.5	3
262	Blood biomarkers to predict short-term pulmonary exacerbation risk in children and adolescents with CF: A pilot study. *Journal of Cystic Fibrosis*, **2020**, 19, 49-51	4.1	4
261	The future of cystic fibrosis care: a global perspective. *Lancet Respiratory Medicine,the*, **2020**, 8, 65-124	35.1	259
260	Lung compartment analysis assessed from N multiple-breath washout in children with cystic fibrosis. *Pediatric Pulmonology*, **2020**, 55, 1671-1680	3.5	1
259	Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. *European Respiratory Journal*, **2020**, 56,	13.6	1
258	Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial. *JAMA Pediatrics*, **2020**, 174, 332-340	8.3	13
257	Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis. *BMC Pediatrics*, **2019**, 19, 369	2.6	8
256	Incidence and risk factors of paediatric cystic fibrosis-related diabetes. *Journal of Cystic Fibrosis*, **2019**, 18, 874-878	4.1	4
255	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. *Clinical Infectious Diseases*, **2019**, 69, 1812-1816	11.6	33
254	Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis. *Journal of Cystic Fibrosis*, **2019**, 18, 790-795	4.1	9
253	Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2019**, 16, 861-867	4.7	7
252	Growth of Pulmonary Arteriovenous Malformations in Pediatric Patients with Hereditary Hemorrhagic Telangiectasia. *Journal of Pediatrics*, **2019**, 208, 279-281	3.6	7
251	Hyperpolarised Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis. *European Respiratory Journal*, **2019**, 53,	13.6	35
250	A two-center analysis of hyperpolarized Xe lung MRI in stable pediatric cystic fibrosis: Potential as a biomarker for multi-site trials. *Journal of Cystic Fibrosis*, **2019**, 18, 728-733	4.1	28
249	Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease. *Academic Radiology*, **2019**, 26, 344-354	4.3	25

248	Effect of changes in tidal volume on multiple breath washout outcomes. *PLoS ONE*, **2019**, 14, e0219309	3.7	7
247	Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis. *Chest*, **2019**, 156, 667-673	5.3	4
246	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Respiratory Medicine,the*, **2019**, 7, 802-809	35.1	34
245	Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators. *Pediatric Pulmonology*, **2019**, 54 Suppl 3, S46-S55	3.5	14
244	A theory for polymicrogyria and brain arteriovenous malformations in HHT. *Neurology*, **2019**, 92, 34-42	6.5	12
243	The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF. *Journal of Cystic Fibrosis*, **2019**, 18, 35-43	4.1	28
242	Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 987-995	10.2	51
241	Eradication of early P. aeruginosa infection in children . *Journal of Cystic Fibrosis*, **2019**, 18, 78-85	4.1	20
240	ECFS best practice guidelines: the 2018 revision. *Journal of Cystic Fibrosis*, **2018**, 17, 153-178	4.1	276
239	Comparison of facemask and mouthpiece interfaces for multiple breath washout measurements. *Journal of Cystic Fibrosis*, **2018**, 17, 511-517	4.1	6
238	Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, e1-e19	10.2	56
237	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 526-528	10.2	21
236	Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis. *Thorax*, **2018**, 73, 451-458	7.3	27
235	The effects of 100% oxygen on breathing pattern are not limited to young children. *European Respiratory Journal*, **2018**, 51,	13.6	3
234	Echocardiography Grading for Pulmonary Arteriovenous Malformation Screening in Children with Hereditary Hemorrhagic Telangiectasia. *Journal of Pediatrics*, **2018**, 195, 288-291.e1	3.6	3
233	Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. *Journal of Cystic Fibrosis*, **2018**, 17, 723-728	4.1	8
232	Reply to Verbanck and Vanderhelst: The Respective Roles of Lung Clearance Index and Magnetic Resonance Imaging in the Clinical Management of Patients with Cystic Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 411-412	10.2	1
231	Ventilation inhomogeneity in infants with recurrent wheezing. *Thorax*, **2018**, 73, 936-941	7.3	7

230	Ivacaftor treatment of cystic fibrosis in children aged 12 to . *Lancet Respiratory Medicine,the*, **2018**, 6, 545-553	35.1	112
229	CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study. *Annals of the American Thoracic Society*, **2018**, 15, 209-216	4.7	20
228	The lung clearance index as a monitoring tool in cystic fibrosis: ready for the clinic?. *Current Opinion in Pulmonary Medicine*, **2018**, 24, 579-585	3	9
227	Lung clearance index is elevated in young children with symptom-controlled asthma. *Health Science Reports*, **2018**, 1, e58	2.2	8
226	Reference equations for the interpretation of forced expiratory and plethysmographic measurements in infants. *Pediatric Pulmonology*, **2018**, 53, 907-916	3.5	4
225	Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population. *Annals of the American Thoracic Society*, **2018**, 15, 827-836	4.7	8
224	Correlation of Lung Clearance Index with Hyperpolarized Xe Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1073-1075	10.2	43
223	Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. *Journal of Cystic Fibrosis*, **2017**, 16, 492-495	4.1	7
222	Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. *Journal of Cystic Fibrosis*, **2017**, 16, 395-400	4.1	33
221	Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2017**, 14, 1412-1418	4.7	22
220	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. *The Cochrane Library*, **2017**, 6, CD006961	5.2	2
219	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. *Lancet Respiratory Medicine,the*, **2017**, 5, 557-567	35.1	176
218	Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis. *Journal of Pediatrics*, **2017**, 184, 165-171.e1	3.6	19
217	Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. *Thorax*, **2017**, 72, 327-332	7.3	38
216	Validation of multiple breath washout devices. *Journal of Cystic Fibrosis*, **2017**, 16, e22-e23	4.1	9
215	Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 1216-1225	10.2	88
214	Chronic Hypoxemia in a 2-Year-Old Boy. *Annals of the American Thoracic Society*, **2017**, 14, 1348-1352	4.7	
213	Inter-test reproducibility of the lung clearance index measured by multiple breath washout. *European Respiratory Journal*, **2017**, 50,	13.6	33

212	False-Positive Newborn Screening for Cystic Fibrosis and Health Care Use. *Pediatrics*, **2017**, 140,	7.4	20
211	Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations. *European Respiratory Journal*, **2017**, 50,	13.6	12
210	Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia. *Npj Genomic Medicine*, **2017**, 2, 12	6.2	46
209	Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial. *Trials*, **2017**, 18, 293	2.8	11
208	Orkambi and amplifier co-therapy improves function from a rare mutation in gene-edited cells and patient tissue. *EMBO Molecular Medicine*, **2017**, 9, 1224-1243	12	76
207	A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis. *Genetics in Medicine*, **2017**, 19, 403-411	8.1	7
206	Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2017**, 16, 58-63	4.1	11
205	Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 912-920	10.2	95
204	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. *The Cochrane Library*, **2017**, 10, CD009528	5.2	16
203	Correcting for tissue nitrogen excretion in multiple breath washout measurements. *PLoS ONE*, **2017**, 12, e0185553	3.7	18
202	How Best to Capture Early Cystic Fibrosis Lung Disease?. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 283-284	10.2	1
201	Physiologic endpoints for clinical studies for cystic fibrosis. *Journal of Cystic Fibrosis*, **2016**, 15, 416-23	4.1	48
200	Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. *European Respiratory Journal*, **2016**, 47, 829-36	13.6	46
199	A Systematic Approach to Multiple Breath Nitrogen Washout Test Quality. *PLoS ONE*, **2016**, 11, e0157523	3.7	35
198	Changes in multiple breath washout measures after raised volume rapid thoracoabdominal compression maneuvers in infants. *Pediatric Pulmonology*, **2016**, 51, 183-8	3.5	6
197	Utility of MDCT MIP Postprocessing Reconstruction Images in Children With Hereditary Hemorrhagic Telangiectasia. *Journal of Computer Assisted Tomography*, **2016**, 40, 375-9	2.2	6
196	Lung clearance index response in patients with CF with class III CFTR mutations. *Thorax*, **2016**, 71, 476-7	7.3	11
195	Constrictive Bronchiolitis: A Distinct Phenotype of Cystic Fibrosis Lung Disease?. *Annals of the American Thoracic Society*, **2016**, 13, 2111-2112	4.7	

194	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *The Cochrane Library*, **2016**, 12, CD010004	5.2	6
193	Clinimetric Properties of the Lung Clearance Index in Adults and Children With Cystic Fibrosis. *Chest* , **2016**, 150, 1412-1413	5.3	1
192	A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. *Respiratory Medicine*, **2016**, 112, 59-64	4.6	25
191	Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. *Journal of Cystic Fibrosis*, **2016**, 15, 386-91	4.1	8
190	Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis. *Pediatrics*, **2016**, 138,	7.4	17
189	Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. *Human Molecular Genetics*, **2016**, 25, 4590-4600	5.6	62
188	Standardy opieki Europejskiego Towarzystwa Mukowiscydozy: wytyczne i najlepsze praktyki. *Pediatria Polska*, **2016**, 91, S30-S53	0.1	
187	Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. *Expert Review of Respiratory Medicine*, **2016**, 10, 1221-1228	3.8	5
186	Pulmonary artery hypertension: an underrated disease manifestation in cystic fibrosis?. *Lancet Respiratory Medicine,the*, **2016**, 4, 596-598	35.1	3
185	Cystic fibrosis. *Nature Reviews Disease Primers*, **2015**, 1, 15010	51.1	258
184	Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2015**, 14, 755-62	4.1	47
183	Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. *Journal of Cystic Fibrosis*, **2015**, 14, 608-14	4.1	10
182	Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. *Annals of the American Thoracic Society*, **2015**, 12, 1398-406	4.7	28
181	Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. *Journal of Cystic Fibrosis*, **2015**, 14, 403-11	4.1	19
180	Inconclusive diagnosis of cystic fibrosis after newborn screening. *Pediatrics*, **2015**, 135, e1377-85	7.4	75
179	Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. *Stroke*, **2015**, 46, 1362-4	6.7	48
178	Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. *European Respiratory Journal*, **2015**, 46, 1055-64	13.6	41
177	Effect of equipment dead space on multiple breath washout measures. *Respirology*, **2015**, 20, 459-66	3.6	22

176	Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. *Journal of Cystic Fibrosis*, **2015**, 14, 770-6	4.1	31
175	Newborn screening for cystic fibrosis. *Expert Review of Respiratory Medicine*, **2015**, 9, 619-31	3.8	17
174	Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2015**, 14, 727-32	4.1	24
173	Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2015**, 14, 262-6	4.1	36
172	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2015**, CD009528		13
171	Tiotropium bromide for cystic fibrosis. *Expert Opinion on Orphan Drugs*, **2015**, 3, 957-966	1.1	
170	Commentaries on Viewpoint: Using the same cut-off for sulfur hexafluoride and nitrogen multiple-breath washout may not be appropriate. *Journal of Applied Physiology*, **2015**, 119, 1513-4	3.7	4
169	Author's Response: Re: Stratifying Cystic Fibrosis Risk for Newborn Screen Infants With Equivocal Sweat Chloride Levels. *Pediatrics*, **2015**, 136, e1490-1	7.4	
168	Response to letter. *Pediatric Pulmonology*, **2015**, 50, 105	3.5	1
167	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2015**, CD006961		5
166	Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. *New England Journal of Medicine*, **2015**, 373, 220-31	59.2	910
165	Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. *Annals of the American Thoracic Society*, **2015**, 12, 932-9	4.7	66
164	Pulmonary exacerbations and parent-reported outcomes in children . *Pediatric Pulmonology*, **2015**, 50, 236-243	3.5	13
163	Novel outcome measures for clinical trials in cystic fibrosis. *Pediatric Pulmonology*, **2015**, 50, 302-315	3.5	29
162	Alternative outcomes for the multiple breath washout in children with CF. *Journal of Cystic Fibrosis*, **2015**, 14, 490-6	4.1	29
161	Pulmonary Exacerbations in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2015**, 12 Suppl 2, S200-6	4.7	42
160	Basic science: What will it deliver? Non-gene therapy treatments **2015**, 620-624		
159	Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. *Journal of Cystic Fibrosis*, **2014**, 13, 172-8	4.1	24

158	Pulmonary exacerbations in CF patients with early lung disease. *Journal of Cystic Fibrosis*, **2014**, 13, 74-9	4.1	20
157	Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). *Lancet Respiratory Medicine,the*, **2014**, 2, 902-910	35.1	150
156	Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. *European Respiratory Journal*, **2014**, 43, 817-23	13.6	78
155	Pooled analysis of tiotropium Respimat( ) pharmacokinetics in cystic fibrosis. *Pulmonary Pharmacology and Therapeutics*, **2014**, 29, 217-23	3.5	5
154	Emerging drugs for cystic fibrosis. *Expert Opinion on Emerging Drugs*, **2014**, 19, 143-55	3.7	18
153	The cystic fibrosis gender gap: potential roles of estrogen. *Pediatric Pulmonology*, **2014**, 49, 309-17	3.5	37
152	Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis. *Journal of Cystic Fibrosis*, **2014**, 13, 542-9	4.1	12
151	The diagnostic yield of rescreening for arteriovenous malformations in children with hereditary hemorrhagic telangiectasia. *Journal of Pediatrics*, **2014**, 165, 197-9	3.6	17
150	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. *Journal of Cystic Fibrosis*, **2014**, 13 Suppl 1, S23-42	4.1	328
149	Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. *Annals of the American Thoracic Society*, **2014**, 11, 1120-9	4.7	119
148	Lung arginase expression and activity is increased in cystic fibrosis mouse models. *Journal of Applied Physiology*, **2014**, 117, 284-8	3.7	11
147	Is there a role for antimicrobial stewardship in cystic fibrosis?. *Annals of the American Thoracic Society*, **2014**, 11, 1116-9	4.7	12
146	Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. *Annals of the American Thoracic Society*, **2014**, 11, 1298-306	4.7	58
145	Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. *Annals of the American Thoracic Society*, **2014**, 11, 1640-50	4.7	133
144	Inhaled liposomal amikacin. *Expert Review of Respiratory Medicine*, **2014**, 8, 401-9	3.8	33
143	Multitracer stable isotope quantification of arginase and nitric oxide synthase activity in a mouse model of pseudomonas lung infection. *Mediators of Inflammation*, **2014**, 2014, 323526	4.3	5
142	Testing two different doses of tiotropium Respimat in cystic fibrosis: phase 2 randomized trial results. *PLoS ONE*, **2014**, 9, e106195	3.7	10
141	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2014**, CD010004		8

140	The prevalence of asthma in Canadian children of South Asian descent. *Pediatric Pulmonology*, **2014**, 49, 43-8	3.5	5
139	Physiological correlates of pulmonary function in children with cystic fibrosis. *Pediatric Pulmonology*, **2014**, 49, 878-84	3.5	10
138	Positional oximetry to screen for pulmonary arteriovenous malformations in HHT. *Thorax*, **2014**, 69, 1045	7.3	2
137	Effect of arginase inhibition on pulmonary L-arginine metabolism in murine Pseudomonas pneumonia. *PLoS ONE*, **2014**, 9, e90232	3.7	15
136	ATS core curriculum 2014: part IV. Pediatric pulmonary medicine. *Annals of the American Thoracic Society*, **2014**, 11, 1633-9	4.7	
135	Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. *Lancet Respiratory Medicine,the*, **2013**, 1, 630-638	35.1	156
134	Prevalence of pulmonary arteriovenous malformations in children versus adults with hereditary hemorrhagic telangiectasia. *Journal of Pediatrics*, **2013**, 163, 282-4	3.6	15
133	Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. *The Cochrane Library*, **2013**, CD007168	5.2	39
132	Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. *Thorax*, **2013**, 68, 746-51	7.3	60
131	Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2013**, 12, 482-6	4.1	85
130	Brain arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia: clinical presentation and anatomical distribution. *Pediatric Neurology*, **2013**, 49, 445-50	2.9	21
129	Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. *Contemporary Clinical Trials*, **2013**, 36, 99-105	2.3	7
128	Acute antibiotic use in cystic fibrosis clinical trials: does it affect our assessment of clinical efficacy?. *Lancet Respiratory Medicine,the*, **2013**, 1, 98-9	35.1	2
127	Early lung disease in cystic fibrosis. *Lancet Respiratory Medicine,the*, **2013**, 1, 148-57	35.1	58
126	Update in cystic fibrosis 2012. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 915-9	20.2	25
125	Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2013**, 12, 575-83	4.1	24
124	Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?. *European Respiratory Journal*, **2013**, 42, 527-38	13.6	42
123	Consensus statement for inert gas washout measurement using multiple- and single- breath tests. *European Respiratory Journal*, **2013**, 41, 507-22	13.6	449

122	Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 456-60	10.2	118
121	Aquagenic wrinkling of the palms in a patient with cystic fibrosis. *New England Journal of Medicine*, **2013**, 369, 2362-3	59.2	13
120	Multiple breath nitrogen washout: a feasible alternative to mass spectrometry. *PLoS ONE*, **2013**, 8, e56868	3.7	72
119	Utility of contrast echocardiography for pulmonary arteriovenous malformation screening in pediatric hereditary hemorrhagic telangiectasia. *Journal of Pediatrics*, **2012**, 160, 1039-43.e1	3.6	24
118	Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. *The Cochrane Library*, **2012**, 12, CD007481	5.2	3
117	Update in cystic fibrosis 2011. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 933-6	10.2	9
116	Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species. *Medical Mycology*, **2012**, 50, 658-60	3.9	15
115	Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. *Nature Biotechnology*, **2012**, 30, 876-82	44.5	292
114	Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 8-13	4.1	58
113	Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2012**, 11, 63-7	4.1	19
112	Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 78-83	4.1	52
111	Does earlier lobectomy result in better long-term pulmonary function in children with congenital lung anomalies? A prospective study. *Journal of Pediatric Surgery*, **2012**, 47, 852-6	2.6	33
110	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2012**, 11, CD009528		17
109	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. *Journal of Cystic Fibrosis* , **2012**, 11, 539-49	4.1	68
108	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2012**, 12, CD010004		10
107	Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. *PLoS ONE*, **2012**, 7, e36077	3.7	54
106	Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. *Pediatric Pulmonology*, **2012**, 47, 641-8	3.5	36
105	Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. *European Respiratory Journal*, **2012**, 40, 61-6	13.6	146

104	Nitric oxide and L-arginine deficiency in cystic fibrosis. *Current Pharmaceutical Design*, **2012**, 18, 726-36	3.3	37
103	Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT. *Radiology*, **2012**, 264, 868-75	20.5	38
102	Cystic fibrosis: the role of the small airways. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2012**, 25, 261-4	3.8	11
101	Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2012**, 307, 2269-77	27.4	127
100	Juvenile polyposis syndrome, SMAD4 mutations, and hereditary hemorrhagic telangiectasia. *Journal of Pediatric Gastroenterology and Nutrition*, **2012**, 54, 120-2	2.8	9
99	New therapies in cystic fibrosis. *Current Pharmaceutical Design*, **2012**, 18, 614-27	3.3	19
98	Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. *Chest*, **2012**, 142, 1259-1266	5.3	86
97	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis **2012**,		4
96	L-ornithine derived polyamines in cystic fibrosis airways. *PLoS ONE*, **2012**, 7, e46618	3.7	31
95	Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome. *PLoS ONE*, **2012**, 7, e51050	3.7	5
94	Diagnostic value of nasal nitric oxide measured with non-velum closure techniques for children with primary ciliary dyskinesia. *Journal of Pediatrics*, **2011**, 159, 420-4	3.6	51
93	Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis. *Pediatric Pulmonology*, **2011**, 46, 489-96	3.5	15
92	The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. *Pediatric Pulmonology*, **2011**, 46, 554-8	3.5	14
91	Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. *Pediatric Pulmonology*, **2011**, 46, 666-71	3.5	24
90	Effect of endoscopic sinus surgery on pulmonary function and microbial pathogens in a pediatric population with cystic fibrosis. *JAMA Otolaryngology*, **2011**, 137, 542-7		31
89	Skeletal muscle metabolism in cystic fibrosis and primary ciliary dyskinesia. *Pediatric Research*, **2011**, 69, 40-5	3.2	47
88	Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1363-8	10.2	43
87	A comparison of amount and speed of deposition between the PARI LC STAR® jet nebulizer and an investigational eFlow® nebulizer. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2011**, 24, 157-63	3.8	28

86	Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. *Journal of Clinical Microbiology*, **2011**, 49, 2772-3	9.7	8
85	Symptomatic liver involvement in neonatal hereditary hemorrhagic telangiectasia. *Pediatrics*, **2011**, 127, e1615-20	7.4	19
84	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *New England Journal of Medicine*, **2011**, 365, 1663-72	59.2	1465
83	Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 635-40	10.2	119
82	Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. *Thorax*, **2010**, 65, 379-83	7.3	156
81	The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. *Chest*, **2010**, 137, 171-6	5.3	273
80	Exhaled nitric oxide in pulmonary diseases: a comprehensive review. *Chest*, **2010**, 138, 682-92	5.3	281
79	Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2010**, 303, 1707-15	27.4	238
78	Alveolar inflammation in cystic fibrosis. *Journal of Cystic Fibrosis*, **2010**, 9, 217-27	4.1	90
77	Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. *Thorax*, **2010**, 65, 286-91	7.3	200
76	Emerging therapies for cystic fibrosis lung disease. *Expert Opinion on Emerging Drugs*, **2010**, 15, 653-9	3.7	27
75	Sputum induction in routine clinical care of children with cystic fibrosis. *Journal of Pediatrics*, **2010**, 157, 1006-1011.e1	3.6	37
74	Potential of Denufosol as an Early Intervention Therapy for CF Lung Disease. *FASEB Journal*, **2010**, 24, 31.9	0.9	1
73	The approach to Pseudomonas aeruginosa in cystic fibrosis. *Seminars in Respiratory and Critical Care Medicine*, **2009**, 30, 587-95	3.9	26
72	Update in cystic fibrosis 2008. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 445-8	10.2	16
71	Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis. *Pediatric Pulmonology*, **2009**, 44, 939-40	3.5	20
70	Exercise and physical activity in children with cystic fibrosis. *Paediatric Respiratory Reviews*, **2009**, 10, 105-9	4.8	74
69	Pulmonary function after early vs late lobectomy during childhood: a preliminary study. *Journal of Pediatric Surgery*, **2009**, 44, 893-5	2.6	37

68	Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. *Journal of Cystic Fibrosis*, **2009**, 8, 361-9	4.1	66
67	Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2009**, CD007168		29
66	Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2009**, CD007481		7
65	Cystic fibrosis: pathogenesis and future treatment strategies. *Respiratory Care*, **2009**, 54, 595-605	2.1	106
64	Recent advances in cystic fibrosis. *Paediatric Respiratory Reviews*, **2008**, 9, 144-8	4.8	31
63	Cystic fibrosis: a review of pulmonary and nutritional therapies. *Advances in Pediatrics*, **2008**, 55, 99-121	2.2	7
62	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. *Cochrane Database of Systematic Reviews*, **2008**, CD006961		7
61	MRI: the next frontier for cystic fibrosis clinicians?. *Expert Review of Respiratory Medicine*, **2008**, 2, 179-82	3.8	1
60	Reduced lung function in cystic fibrosis: a primary or secondary phenotype?. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 2-3	10.2	12
59	Amiloride: still a viable treatment option in cystic fibrosis?. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 1191-2	10.2	6
58	A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. *Canadian Respiratory Journal*, **2008**, 15, 259-62	2.1	19
57	Reliability and validity of the habitual activity estimation scale (HAES) in patients with cystic fibrosis. *Pediatric Pulmonology*, **2008**, 43, 345-53	3.5	38
56	Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. *Pediatric Pulmonology*, **2008**, 43, 753-9	3.5	33
55	Assessment of body composition in pediatric patients with cystic fibrosis. *Pediatric Pulmonology*, **2008**, 43, 1025-32	3.5	10
54	Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. *Pediatric Pulmonology*, **2008**, 43, 1224-32	3.5	34
53	Massive hemoptysis in an 11-year-old girl with isolated pulmonary arteritis. *Pediatric Pulmonology*, **2007**, 42, 177-80	3.5	7
52	Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. *Pediatric Pulmonology*, **2007**, 42, 249-55	3.5	60
51	Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. *Pediatric Pulmonology*, **2007**, 42, 471-6	3.5	48

50	Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patients. *Journal of Clinical Microbiology*, **2007**, 45, 2979-84	9.7	24
49	Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. *Journal of Antimicrobial Chemotherapy*, **2007**, 59, 1135-40	5.1	19
48	Exhaled nitric oxide in children after accidental exposure to chlorine gas. *Inhalation Toxicology*, **2007**, 19, 895-8	2.7	9
47	Inhalation of Moli1901 in patients with cystic fibrosis. *Chest*, **2007**, 131, 1461-6	5.3	103
46	A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. *Pediatrics*, **2007**, 119, e1230-8	7.4	40
45	New pulmonary therapies for cystic fibrosis. *Current Opinion in Pulmonary Medicine*, **2007**, 13, 541-6	3	21
44	Mucolytics in cystic fibrosis. *Paediatric Respiratory Reviews*, **2007**, 8, 24-9	4.8	104
43	Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 208-12	10.2	69
42	Restoring airway surface liquid in cystic fibrosis. *New England Journal of Medicine*, **2006**, 354, 291-3	59.2	61
41	Pharmacokinetics of inhaled colistin in patients with cystic fibrosis: authors' response. *Journal of Antimicrobial Chemotherapy*, **2006**, 58, 223-223	5.1	3
40	Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. *Journal of Antimicrobial Chemotherapy*, **2006**, 57, 306-11	5.1	686
39	Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. *Expert Review of Anti-Infective Therapy*, **2006**, 4, 807-19	5.5	39
38	Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. *Respiratory Research* , **2006**, 7, 87	7.3	44
37	Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. *Journal of Pediatrics*, **2006**, 149, 142	3.6	8
36	What's new in CF airway inflammation: an update. *Paediatric Respiratory Reviews*, **2006**, 7 Suppl 1, S70-2	4.8	24
35	Diagnosing and managing infection in CF. *Paediatric Respiratory Reviews*, **2006**, 7 Suppl 1, S151-3	4.8	23
34	P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca2+ influx. *Pharmacogenetics and Genomics*, **2006**, 16, 199-205	1.9	20
33	Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. *Current Opinion in Pulmonary Medicine*, **2006**, 12, 428-32	3	41

32	Comparison of throat swabs and nasopharyngeal suction specimens in non-sputum-producing patients with cystic fibrosis. *Pediatric Pulmonology*, **2006**, 41, 839-43	3.5	17
31	Beta2-agonists for asthma: the pediatric perspective. *Clinical Reviews in Allergy and Immunology*, **2006**, 31, 209-18	12.3	10
30	Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. *Respiratory Research*, **2005**, 6, 133	7.3	24
29	Human adenosine 2B receptor: SNP discovery and evaluation of expression in patients with cystic fibrosis. *Pharmacogenetics and Genomics*, **2005**, 15, 321-7	1.9	8
28	Increased arginase activity in cystic fibrosis airways. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 1523-8	10.2	98
27	Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. *Journal of Infectious Diseases*, **2005**, 191, 1988-91	7	91
26	Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 1000-5	10.2	62
25	Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 822-8	10.2	96
24	Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 719-25	10.2	135
23	Gender-specific disease modification by NOS3. *British Journal of Haematology*, **2004**, 126, 160; author reply 161	4.5	4
22	Microaspiration in infants with laryngomalacia. *Laryngoscope*, **2004**, 114, 1592-6	3.6	16
21	Early interventions in CF. *Pediatric Pulmonology*, **2004**, 26, 88-90	3.5	4
20	Dornase in non-CF. *Pediatric Pulmonology*, **2004**, 26, 154-5	3.5	6
19	Effects of sex and of gene variants in constitutive nitric oxide synthases on exhaled nitric oxide. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1113-6	10.2	39
18	Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 390-4	10.2	50
17	Cystic fibrosis. *Lancet, The*, **2003**, 361, 681-9	40	800
16	Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 387-90	10.2	78
15	beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. *Pharmacogenetics and Genomics*, **2002**, 12, 347-53		52

14	Airway nitric oxide in Duchenne muscular dystrophy. *Journal of Pediatrics*, **2002**, 141, 132-4	3.6	6
13	Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. *Lancet, The*, **2001**, 358, 983-4	40	184
12	Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. *Pediatric Infectious Disease Journal*, **2001**, 20, 320-1	3.4	17
11	Airway nitric oxide in infants with acute wheezy bronchitis. *Pediatric Allergy and Immunology*, **2000**, 11, 230-5	4.2	20
10	Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 162, 2172-6	10.2	94
9	Cystic fibrosis lung disease: the role of nitric oxide. *Pediatric Pulmonology*, **1999**, 28, 442-8	3.5	36
8	Tuberculoma of the pons. *Pediatric Neurology*, **1999**, 20, 57-9	2.9	10
7	Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. *Journal of Pediatrics*, **1999**, 135, 770-2	3.6	86
6	Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. *Pediatric Pulmonology*, **1998**, 25, 88-92	3.5	144
5	Genetic diversity among isolates of Aspergillus fumigatus in patients with cystic fibrosis. *Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology*, **1997**, 285, 450-5		13
4	Single-lung transplantation in a patient with cystic fibrosis and an asymmetric thorax. *Annals of Thoracic Surgery*, **1997**, 64, 1456-8; discussion 1458-9	2.7	25
3	Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. *Human Genetics*, **1997**, 100, 365-77	6.3	215
2	Bronchoalveolar lavage: Don't forget the size of the bronchoscope. *Pediatric Pulmonology*, **1996**, 22, 330-331	3.5	
1	The effect of rapid thoracoabdominal compressions on intracranial pressure in newborn lambs. *Pediatric Research*, **1995**, 38, 664-7	3.2	4